MTHFR 677 CT/MTHFR 1298 CC genotypes are associated with increased risk of hypertension in Indians
- 430 Downloads
The goals of our present study were to measure plasma homocysteine levels and determine their association with methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms (C677T and A1298C) in essential hypertensive subjects. Plasma total homocysteine and folic acid levels were measured in essential hypertensive patients (n = 153) before and after oral supplementation with either 5 mg folic acid tablet/day or 5 mg placebo/day for 4 weeks and compared with age and sex matched normotensive controls (n = 133). MTHFR gene polymorphisms (C677T and A1298C) were studied by restriction fragment length polymorphism and correlated with plasma homocysteine levels. Homocysteine levels were significantly higher in hypertensive patients as compared to controls and showed a negative correlation with plasma folate levels. Folic acid supplementation (5 mg/day) for 4 weeks resulted in a significant decrease in plasma homocysteine concentrations in these patients. Patients carrying MTHFR 677T allele (OR = 1.90; 95%CI: 1.14–3.19) or MTHFR 1298C (OR = 2.6, 95%CI: 1.55–4.40) allele were at increased risk of hypertension. The frequency of co-occurrence of MTHFR 677 CT/1298 CC genotypes was significantly higher in the patients compared to controls (P < 0.05) and was associated with increased risk of hypertension (OR = 3.54, 95%CI: 0.37–4.30). Subjects with MTHFR 1298 CC genotype had significantly higher homocysteine levels compared to those with MTHFR 1298 AA genotype (P < 0.05). Our results indicate that MTHFR 677T and 1298C alleles and co-occurrence of MTHFR 677 CT/MTHFR 1298 CC genotypes are associated with increased risk of hypertension and MTHFR 1298 CC genotype is associated with higher homocysteine levels in our subjects.
KeywordsMethylenetetrahydrofolate reductase (MTHFR) Homocysteine Folate MTHFR C677T MTHFR A1298C
Supported by research funding from Indian Council of Medical Research, New Delhi, India.
- 3.Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Guillou J, Charpiot P, Bodard H, Ghiringhelli O, Calaf R, Luccioni R, Garçon D (1995) Hyperhomocysteinemia-induced vascular damage in the mini pig: captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 91:1161–1174PubMedGoogle Scholar
- 7.van Dijk RA, Rauwerda JA, Steyn M, Twisk JW, Stehouwer CD (2001) Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-controlled trial. Arterioscler Thromb Vasc Biol 21:2072–2079PubMedGoogle Scholar
- 8.Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma RRJ, Boers GH, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales LAC, Parrot RFM, Tan KS, Higgins I, Garcon D, Andria G (1997) Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 277:1775–1781PubMedCrossRefGoogle Scholar
- 18.Jiang S, Hsu YH, Niu T, Xu X, Xing H, Chen C, Wang X, Zhang Y, Peng S, Xu X (2005) A common haplotype on methylenetetrahydrofolate reductase gene modifies the effect of angiotensin-converting enzyme inhibitor on blood pressure in essential hypertension patients-a family-based association study. Clin Exp Hypertens 27:509–521PubMedCrossRefGoogle Scholar
- 19.Lahiri DK, Nurnberger JI (1991) A rapid non-enzymatic method for the preparation of high molecular weight DNA from blood for RFLP studies. Nucleic Acids Res 355:523–527Google Scholar
- 21.Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Guillou J, Charpiot P, Bodard H, Ghiringhelli O, Calaf R, Luccioni R, Garçon D (1995) Hyperhomocysteinemia-induced vascular damage in the minipig: captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 91:1161–1174PubMedGoogle Scholar
- 25.Verhoef P, Kok FJ, Kluijtmans LA, Blom HJ, Refsum H, Ueland PM, Kruyssen DA (1997) The 677C > T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis 132:105–113PubMedCrossRefGoogle Scholar
- 26.Dedoussis GV, Panagiotakos DB, Chrysohoou C, Pitsavos C, Zampelas A, Choumerianou D, Stefanadis C (2004) Effect of interaction between adherence to a Mediterranean diet and the methylenetetrahydrofolate reductase 677C > T mutation on homocysteine concentrations in healthy adults: the ATTICA Study. Am J Clin Nutr 80:849–854PubMedGoogle Scholar
- 27.Inamoto N, Katsuya T, Kokubo Y, Mannami T, Asai T, Baba S, Ogata J, Tomoike H, Ogihara T (2003) Association of methylenetetrahydrofolate reductase gene polymorphism with carotid atherosclerosis depending on smoking status in a Japanese general population. Stroke 34:1628–1633PubMedCrossRefGoogle Scholar
- 28.Benes P, Kankova K, Muzik J, Groch L, Benedik J, Elbl L, Izakovicova-Holla L, Vasku A, Znojil V, Vacha J (2001) Methylenetetrahydrofolate reductase polymorphism, type II diabetes mellitus, coronary artery disease, and essential hypertension in the Czech population. J Mol Genet Metab 73:188–195CrossRefGoogle Scholar
- 32.Lievers KJ, Boers GH, Verhoef P, Heijer DM, Kluijtmans LA, Put VNM, Trijbels FJ, Blom HJ (2001) A second common variant in the methylenetetrahydrofolate reductase (MTHFR) gene and its relationship to MTHFR enzyme activity, homocysteine, and cardiovascular disease risk. J Mol Med 79:522–528PubMedCrossRefGoogle Scholar